Bank of America Reaffirms "Underperform" Rating for Hims & Hers Health (NYSE:HIMS)

Bank of America reiterated their underperform rating on shares of Hims & Hers Health (NYSE:HIMS - Free Report) in a research note published on Thursday,Benzinga reports. They currently have a $21.00 price target on the stock.

Other equities analysts have also issued reports about the company. BTIG Research began coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 target price on the stock. Piper Sandler upped their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Morgan Stanley lowered Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their target price for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Leerink Partners upped their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Finally, TD Cowen reiterated a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $37.23.

Remove Ads

Hims & Hers Health Stock Up 4.7 %

Shares of NYSE:HIMS traded up $1.62 during midday trading on Thursday, reaching $36.01. 23,509,501 shares of the company traded hands, compared to its average volume of 13,182,499. Hims & Hers Health has a 12 month low of $11.20 and a 12 month high of $72.98. The firm has a market capitalization of $8.00 billion, a price-to-earnings ratio of 81.85 and a beta of 1.37. The firm's fifty day moving average price is $37.64 and its two-hundred day moving average price is $27.60.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 78,127 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74. Following the completion of the sale, the chief executive officer now owns 109,956 shares in the company, valued at approximately $3,256,896.72. This trade represents a 41.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Michael Chi sold 7,259 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $32.25, for a total value of $234,102.75. Following the completion of the sale, the insider now owns 184,947 shares of the company's stock, valued at approximately $5,964,540.75. This trade represents a 3.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,062,011 shares of company stock worth $36,892,724 in the last ninety days. 17.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $28,000. Raleigh Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.